Analysts expect Biomerica, Inc. (NASDAQ:BMRA) to report earnings per share (EPS) of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Biomerica’s earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at ($0.04). Biomerica posted earnings of ($0.08) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 25%. The company is expected to issue its next quarterly earnings results on Friday, September 4th.
According to Zacks, analysts expect that Biomerica will report full year earnings of ($0.25) per share for the current year, with EPS estimates ranging from ($0.26) to ($0.23). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.10) per share, with EPS estimates ranging from ($0.33) to $0.13. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Biomerica.
Separately, B. Riley upped their price target on shares of Biomerica from $6.25 to $11.00 in a research note on Friday, June 5th.
Biomerica stock opened at $9.11 on Thursday. Biomerica has a fifty-two week low of $2.05 and a fifty-two week high of $23.39. The firm has a market capitalization of $107.04 million, a PE ratio of -33.74 and a beta of -0.84. The company’s 50-day moving average is $8.05 and its 200-day moving average is $6.01. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.00 and a quick ratio of 1.86.
A number of institutional investors and hedge funds have recently made changes to their positions in BMRA. Heritage Investors Management Corp increased its position in shares of Biomerica by 79.4% during the second quarter. Heritage Investors Management Corp now owns 68,450 shares of the company’s stock worth $496,000 after buying an additional 30,300 shares during the period. Morgan Stanley bought a new stake in Biomerica during the first quarter valued at approximately $115,000. Wells Fargo & Company MN lifted its holdings in shares of Biomerica by 22.3% in the 1st quarter. Wells Fargo & Company MN now owns 7,950 shares of the company’s stock worth $56,000 after acquiring an additional 1,450 shares during the last quarter. Geode Capital Management LLC bought a new stake in Biomerica during the 1st quarter valued at $352,000. Finally, Creative Planning purchased a new position in Biomerica during the 1st quarter valued at $122,000. Institutional investors and hedge funds own 5.19% of the company’s stock.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Read More: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.